MAB-22
- Generic Name
- MAB-22
Study to Compare the Efficacy, Pharmacokinetics, Pharmacodynamics, Safety, and Immunogenicity of MAB-22 Versus Prolia®
- First Posted Date
- 2024-07-17
- Last Posted Date
- 2025-05-11
- Lead Sponsor
- Xentria, Inc.
- Target Recruit Count
- 440
- Registration Number
- NCT06504966
Single Dose, Three-arm Study to Compare the Pharmacokinetic Similarity of MAB-22 Versus Prolia®
Phase 1
Recruiting
- Conditions
- Healthy Participants
- Interventions
- First Posted Date
- 2024-03-15
- Last Posted Date
- 2024-11-13
- Lead Sponsor
- Xentria, Inc.
- Target Recruit Count
- 225
- Registration Number
- NCT06310824
- Locations
- 🇳🇱
Xentria Investigative Site, Groningen, Netherlands
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath